Pharmaceutical company
Appears in 1 story · Last updated Oct 27, 2026
Global partner holding ex-Greater-China rights to sac-TMT
Patients with EGFR-mutant lung cancer whose disease progressed on targeted therapy lived a median 25.9 months on sac-TMT, against 17.4 months on platinum doublet chemotherapy. Those are the final overall survival figures from the 376-patient OptiTROP-Lung04 trial, presented at the 2026 ESMO Congress in Madrid by Wenfeng Fang of Sun Yat-sen University Cancer Center.
Updated Oct 27
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
